162 related articles for article (PubMed ID: 16998461)
1. Immunohistochemical markers in diagnosis of papillary thyroid carcinoma: Utility of HBME1 combined with CK19 immunostaining.
Nasr MR; Mukhopadhyay S; Zhang S; Katzenstein AL
Mod Pathol; 2006 Dec; 19(12):1631-7. PubMed ID: 16998461
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors.
Prasad ML; Pellegata NS; Huang Y; Nagaraja HN; de la Chapelle A; Kloos RT
Mod Pathol; 2005 Jan; 18(1):48-57. PubMed ID: 15272279
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
4. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
Sadiq Q; Sekhri R; Dibaba DT; Zhao Q; Agarwal S
World J Surg Oncol; 2021 May; 19(1):143. PubMed ID: 33964951
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical diagnosis of papillary thyroid carcinoma.
Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
[TBL] [Abstract][Full Text] [Related]
6. Hyalinizing trabecular adenoma of the thyroid revisited: a histologic and immunohistochemical study of thyroid lesions with prominent trabecular architecture and sclerosis.
Galgano MT; Mills SE; Stelow EB
Am J Surg Pathol; 2006 Oct; 30(10):1269-73. PubMed ID: 17001158
[TBL] [Abstract][Full Text] [Related]
7. Cytokeratin19 expression discriminates papillary thyroid carcinoma from other thyroid lesions and predicts its aggressive behavior.
Isic Dencic T; Cvejic D; Paunovic I; Tatic S; Havelka M; Savin S
Med Oncol; 2013 Mar; 30(1):362. PubMed ID: 23269585
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical separation of follicular variant of papillary thyroid carcinoma from follicular adenoma.
Nakamura N; Erickson LA; Jin L; Kajita S; Zhang H; Qian X; Rumilla K; Lloyd RV
Endocr Pathol; 2006; 17(3):213-23. PubMed ID: 17308358
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma.
Scognamiglio T; Hyjek E; Kao J; Chen YT
Am J Clin Pathol; 2006 Nov; 126(5):700-8. PubMed ID: 17050067
[TBL] [Abstract][Full Text] [Related]
10. [Expression of GADD153 in follicular tumors of thyroid and comparison with CK19, Galectin-3 and HBME-1].
Tang QS; Teng XD; Ding W; Zhou J; Yao HT; Ying LX; Xu LM
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):745-8. PubMed ID: 22336157
[TBL] [Abstract][Full Text] [Related]
11. [Detection of cytokeratin 19 and thyroperoxidase expressions in the diagnosis of thyroid diseases].
Yang QX; Shao CK; Feng ZY; Huang BQ; Han AJ; Xiong M; Zhao WL; Wu TT
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jun; 25(6):678-81. PubMed ID: 15958307
[TBL] [Abstract][Full Text] [Related]
12. HBME-1 and CK19 are highly discriminatory in the cytological diagnosis of papillary thyroid carcinoma.
Nga ME; Lim GS; Soh CH; Kumarasinghe MP
Diagn Cytopathol; 2008 Aug; 36(8):550-6. PubMed ID: 18618720
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
Cameron BR; Berean KW
J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
[TBL] [Abstract][Full Text] [Related]
14. Differential diagnostic significance of HBME-1, CK19 and S100 in various thyroid lesions.
Palo S; Biligi DS
Malays J Pathol; 2017 Apr; 39(1):55-67. PubMed ID: 28413206
[TBL] [Abstract][Full Text] [Related]
15. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of CK19, HBME-1 and galectin-3 expressions in differential diagnosis of thyroid papillary microcarcinoma from benign lesions].
Tong J; Wang Y; Da JP
Zhonghua Zhong Liu Za Zhi; 2011 Aug; 33(8):599-604. PubMed ID: 22325220
[TBL] [Abstract][Full Text] [Related]
17. Ultrasound Risk Assessment Combined with Molecular Markers of Galectin-3, c-MET, HBME-1 and CK19 for Diagnosis of Malignant and Benign Thyroid Nodules.
Han RL; Wang J; Zhang FJ; Zhao N; Gao BL
Pathol Oncol Res; 2019 Jul; 25(3):1075-1081. PubMed ID: 30361909
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic significance of CK19, TG, Ki67 and galectin-3 expression for papillary thyroid carcinoma in the northeastern region of China.
Song Q; Wang D; Lou Y; Li C; Fang C; He X; Li J
Diagn Pathol; 2011 Dec; 6():126. PubMed ID: 22188859
[TBL] [Abstract][Full Text] [Related]
19. Absence of the BRAF mutation in HBME1+ and CK19+ atypical cell clusters in Hashimoto thyroiditis: supportive evidence against preneoplastic change.
Nasr MR; Mukhopadhyay S; Zhang S; Katzenstein AL
Am J Clin Pathol; 2009 Dec; 132(6):906-12. PubMed ID: 19926583
[TBL] [Abstract][Full Text] [Related]
20. Combined immunohistochemistry for thyroid peroxidase, galectin-3, CK19 and HBME-1 in differential diagnosis of thyroid tumors.
Paunovic I; Isic T; Havelka M; Tatic S; Cvejic D; Savin S
APMIS; 2012 May; 120(5):368-79. PubMed ID: 22515291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
